

# US PATENT & TRADEMARK OFFICE

## PATENT FULL TEXT AND IMAGE DATABASE

<a href="#">Home</a>	<a href="#">Boolean</a>	<a href="#">Manual</a>	<a href="#">Number</a>	<a href="#">Help</a>
	<a href="#">Hit List</a>	<a href="#">Bottom</a>		
<a href="#">View Shopping Cart</a>		<a href="#">Add to Shopping Cart</a>		
	<a href="#">Images</a>			

( 1 of 1 )

# United States Patent

6,011,003

Charnock-Jones, et al.

January 4, 2000

FLT-4(FMS-like tyrosine kinase), FLT-15, variants thereof used as growth factor inhibitors

### Abstract

Disclosed is an altered, soluble form of the FLT polypeptide being capable of binding to VEGF and thereby exerting an inhibitory effect thereon, the polypeptide comprising five or fewer complete immunoglobulin-like domains, together with pharmaceutical compositions comprising the polypeptide, and various uses thereof.

Inventors: **Charnock-Jones; David Stephen** (Cambridge, GB); **Boocock; Christine Ann** (Dundee, GB); **Sharkey; Andrew Mark** (Cambridge, GB); **Smith; Stephen Kevin** (Cambridge, GB)

**Assignee:** **Metris Therapeutics Limited (London, GB)**

Appl. No.: 750141

Filed: May 12, 1997

PCT Filed: **May 26, 1995**

PCT NO: PCT/GB95/01

371 Date: **May 12, 1997**

102(e) Date: **May 12, 1997**

PCT PUB.NO.: WO95/33050

#### Foreign Application Priority Data

May 26, 1994[GB] 9410534

**Current U.S. Class:** 514/2; 435/69.1; 530/350; 536/23.5  
**Intern'l Class:** C07K 014/71  
**Field of Search:** 536/23.5 435/69.1,7,8,361 530/350 514/2 935/9